Vintage receives warning letter
Executive Summary
Vintage Pharmaceuticals has failed to fulfill post-marketing adverse event reporting commitments, a May 26 FDA 1warning letter states. "Our inspection revealed that your firm had never submitted an [adverse drug experience] to FDA" for any ANDA, the letter states. The company said it submitted a response to FDA and views the matter as closed...
You may also be interested in...
Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says
Serious adverse event periodic reports received by the Center for Drug Evaluation & Research increased 20% in 2004, FDA Investigator Thomas Berry said
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.